The drug reaches peak concentration in the blood within three to four hours and has a half-life of roughly 20 hours, which explains why a single morning dose can suppress appetite through most of the day
10.1016/j.phrs.2018.08.012 12 FakhriS.AbbaszadehF.JorjaniM
In 2015, a Cognitive Vitality Report released by the Alzheimers Drug Discovery Foundation stated that two multi-year treatment trials had found that epithalamin, from which epitalon is isolated, had imparted no severe adverse events in older adults, and that preclinical trials supported a favorable safety profile.35 Ten years later, a systematic review published in 2025 stated that information regarding critical issues about this peptides safety is missing.1 In terms of human trials, the best case we have in support of epitalons safety is a 2002 trial involving 162 patients in which no one in the epitalon group reported serious side effects.36 At the same time, the U.S
Pregnancy and breastfeeding Small clinical studies suggest that ALA may be safe during pregnancy at doses up to 600mg/day for several weeks, with no serious adverse effects reported.40 However, larger, long-term studies are lacking, and there is no reliable safety data for breastfeeding